Simcere Pharmaceutical Group-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Simcere Pharmaceutical Group - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013625
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Simcere Pharmaceutical Group (Simcere) is a drug discovery company that manufactures and supplies branded generic and prescription pharmaceutical products. The company offers products in therapeutic areas including anti-tumor, central nervous, anti-infection, cardiovascular, skeletal muscle, and others. Its products include recombinant human endostatin injection, nedaplatin for injection, palonosetron hydrochloride injection, fluorouracil implants and lyvamlodipine besylate tablets, among others. Simcere’s products are used for the treatment of oncology, neurology, infectious diseases, anti-inflammation and cardiovascular disease. The company conducts research and development to develop new drugs. It partners with pharma companies to develop novel anti-VEGF humanized monoclonal antibody. Simcere is headquartered in Nanjing, China.

Simcere Pharmaceutical Group – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Simcere Pharmaceutical Group, Medical Devices Deals, 2011 to YTD 2017 10
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Amgen and Simcere Pharma Enter into Co-Development Agreement 12
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For Orencia 13
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For BMS-795311 15
Simcere Pharma Enters Into Co-Development Agreement With Suzhou NeuPharma 16
Simcere Pharma Enters Into Co-Development Agreement With Nanjing Medical University 17
Equity Offering 18
Simcere Pharma May Raise up to USD128.9 Million in Public Offering of Shares 18
Acquisition 19
Jinsheng Ren And Assure Ahead Investments Completes Acquisition Of Simcere Pharma For US$517 Million In Going Private Transaction 19
Zhuhai Rongding To Acquire Jilin Boda Pharma From Simcere Pharma For US$65 Million 21
Devont Asset Management To Acquire 35% Stake In Shanghai Celgen From Simcere Pharma For US$48 Million 22
Simcere Pharmaceutical Group – Key Competitors 23
Simcere Pharmaceutical Group – Key Employees 24
Simcere Pharmaceutical Group – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 27
Corporate Communications 27
Aug 02, 2016: Simcere Pharma announced appointment of D.r Hua Mu as Chief Officer of Science and President on Research and Development 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Key Facts 2
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Simcere Pharmaceutical Group, Deals By Therapy Area, 2011 to YTD 2017 8
Simcere Pharmaceutical Group, Medical Devices Deals, 2011 to YTD 2017 10
Simcere Pharmaceutical Group, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Amgen and Simcere Pharma Enter into Co-Development Agreement 12
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For Orencia 13
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For BMS-795311 15
Simcere Pharma Enters Into Co-Development Agreement With Suzhou NeuPharma 16
Simcere Pharma Enters Into Co-Development Agreement With Nanjing Medical University 17
Simcere Pharma May Raise up to USD128.9 Million in Public Offering of Shares 18
Jinsheng Ren And Assure Ahead Investments Completes Acquisition Of Simcere Pharma For US$517 Million In Going Private Transaction 19
Zhuhai Rongding To Acquire Jilin Boda Pharma From Simcere Pharma For US$65 Million 21
Devont Asset Management To Acquire 35% Stake In Shanghai Celgen From Simcere Pharma For US$48 Million 22
Simcere Pharmaceutical Group, Key Competitors 23
Simcere Pharmaceutical Group, Key Employees 24
Simcere Pharmaceutical Group, Subsidiaries 25

★海外企業調査レポート[Simcere Pharmaceutical Group-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hitachi Metals, Ltd.:戦略・SWOT・企業財務分析
    Hitachi Metals, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hitachi Metals, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Kuwait Oil Co:企業の戦略的SWOT分析
    Kuwait Oil Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Lensar Inc-医療機器分野:企業M&A・提携分析
    Summary Lensar Inc (Lensar), a subsidiary of Alphaeon Corp is a medical device company that designs, develops and manufactures laser and advanced 3D imaging technology and devices for refractive cataract surgery. The company provides surgeon with superior femtosecond laser technology. It offers vari …
  • Maxim Power Corp.:企業の発電所・SWOT分析2018
    Maxim Power Corp. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • Chr. Hansen Holding A/S:企業の戦略・SWOT・財務分析
    Chr. Hansen Holding A/S - Strategy, SWOT and Corporate Finance Report Summary Chr. Hansen Holding A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • CEDA International Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary CEDA International Corp (CEDA) is an oil and gas company that offers energy services. The company provides services such as turnaround, industrial maintenance, electrical services, exchanger services, hydro-testing and pipe isolation services, and construction services, among others. It also …
  • TransAtlantic Petroleum Ltd (TAT):企業の財務・戦略的SWOT分析
    TransAtlantic Petroleum Ltd (TAT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Guangzhou Wondfo Biotech Co Ltd (300482):医療機器:M&Aディール及び事業提携情報
    Summary Guangzhou Wondfo Biotech Co Ltd (Wondfo) is a biological company that develops, manufactures and supplies rapid diagnostic reagents and related equipment. Its products include rapid quantitative test, immunofluorescent test system, glucose monitoring system, and raw materials. Wondfo also of …
  • Exiqon AS-医療機器分野:企業M&A・提携分析
    Summary Exiqon A/S (Exiqon), a subsidiary of Qiagen NV is a medical device company that develops, manufactures and markets molecular diagnostic test products. The company’s product categories include microRNA research, incRNA research, mRNA research, DNA research, custom oligos and other reagent pro …
  • RWE AG (RWE)-エネルギー分野:企業M&A・提携分析
    Summary RWE AG (RWE) is an energy company that generates, transmits and distributes electricity. The company generates electricity using various sources such as gas, hard coal, lignite, nuclear, hydro, biomass and renewables. It also produces oil, gas and lignite; and distributes and supplies gas. T …
  • Mylan NV (MYL):医療機器:M&Aディール及び事業提携情報
    Summary Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceutical products in multiple forms for various disease conditions related to respiratory and allerg …
  • Acorn Energy, Inc. (ACFN)-石油・ガス分野:企業M&A・提携分析
    Summary Acorn Energy, Inc. (Acorn) is an energy technology holding company which operates electricity delivery, emergency back-up power generation, and remote monitoring and control systems through its subsidiaries. The company develops and produces sonar systems for the defense, HLS, energy and com …
  • Toro Energy Limited (TOE):企業の戦略的SWOT分析
    Toro Energy Limited (TOE) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Oversea-Chinese Banking Corp Ltd:企業の戦略・SWOT・財務情報
    Oversea-Chinese Banking Corp Ltd - Strategy, SWOT and Corporate Finance Report Summary Oversea-Chinese Banking Corp Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Fujikura Ltd.:企業の戦略・SWOT・財務情報
    Fujikura Ltd. - Strategy, SWOT and Corporate Finance Report Summary Fujikura Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • NEC Networks & System Integration Corp (1973):企業の財務・戦略的SWOT分析
    NEC Networks & System Integration Corp (1973) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Oregon Health & Science University-製薬・医療分野:企業M&A・提携分析
    Summary Oregon Health & Science University (OHSU), a subsidiary of Oregon State University is an academic health center that provides medical education, research, patient care and community services. The center’s educational institute offers undergraduate and graduate courses in anesthesiology, derm …
  • Masraf Al Rayan (Q.S.C.):企業の戦略・SWOT・財務情報
    Masraf Al Rayan (Q.S.C.) - Strategy, SWOT and Corporate Finance Report Summary Masraf Al Rayan (Q.S.C.) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • FLSmidth & Co AS (FLS):企業の財務・戦略的SWOT分析
    FLSmidth & Co AS (FLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • San Raffaele Hospital-製薬・医療分野:企業M&A・提携分析
    Summary San Raffaele hospital (San Raffaele), a subsidiary of Vita-Salute San Raffaele University is a clinical scientific university institution that offers education and healthcare services. The institute provides services through the segments clinic, scientific research, patient services, and hos …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆